Adult immunocompetent mice inoculated with Ebola (EBO) or Marburg (MBG) virus do not become ill. A suckling-mouse-passaged variant of EBO Zaire ’76 (‘mouse-adapted EBO-Z’) causes rapidly lethal infection in adult mice after intraperitoneal (i.p.) inoculation, but does not cause apparent disease when inoculated subcutaneously (s.c.). A series of experiments showed that both forms of resistance to infection are mediated by the Type I interferon response. Mice lacking the cell-surface IFN-α/β receptor died within a week after inoculation of EBO-Z ’76, EBO Sudan, MBG Musoke or MBG Ravn, or after s.c. challenge with mouse-adapted EBO-Z. EBO Reston and EBO Ivory Coast did not cause illness, but immunized the mice against subsequent challenge with mouse-adapted EBO-Z. Normal adult mice treated with antibodies against murine IFN-α/β could also be lethally infected with i.p.-inoculated EBO-Z ’76 or EBO Sudan and with s.c.-inoculated mouse-adapted EBO-Z. Severe combined immunodeficient (SCID) mice became ill 3–4 weeks after inoculation with EBO-Z ’76, EBO Sudan or MBG Ravn, but not the other viruses. Treatment with anti-IFN-α/β antibodies markedly accelerated the course of EBO-Z ’76 infection. Antibody treatment blocked the effect of a potent antiviral drug, 3-deazaneplanocin A, indicating that successful filovirus therapy may require the active participation of the Type I IFN response. Mice lacking an IFN-α/β response resemble primates in their susceptibility to rapidly progressive, overwhelming filovirus infection. The outcome of filovirus transfer between animal species appears to be determined by interactions between the virus and the innate immune response.
BaslerC. F.,
WantX.,
MuhlbergerE.,
VolchkovV.,
ParagasJ.,
KlenkH. D.,
Garcia-SastreA.,
PaleseP.2000; The Ebola virus VP35 protein functions as a type I IFN antagonist. Proceedings of the National Academy of Sciences, USA 97:12289–12294
BowenE. T. W.,
PlattG. S.,
SimpsonD. I. H.,
McArdellL. B.,
RaymondR. T.1978a; Ebola haemorrhagic fever: experimental infection of monkeys. Transactions of the Royal Society of Tropical Medicine and Hygiene 72:188–191
BowenE. T. W.,
BaskervilleA.,
CantellK.,
MannG. F.,
SimpsonD. I. H.,
ZuckermanA. J.1978b; The effect of interferon on experimental Ebola virus infection in rhesus monkeys. In Ebola Virus Hemorrhagic Fever pp 245–252 Edited by
PattynS. R.
Amsterdam: Elsevier/North Holland;
BrayM.,
DavisK.,
GeisbertT.,
SchmaljohnC.,
HugginsJ. W.1998; A mouse model for evaluation of Ebola prophylaxis and therapy. Journal of Infectious Diseases 178:651–661
BrayM.,
DriscollJ.,
HugginsJ. W.2000; Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosylhomocysteine hydrolase inhibitor. Antiviral Research 45:135–147
DurbinJ. E.,
HackenmillerR.,
SimonM. C.,
LevyD. E.1996; Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84:443–450
FreseM.,
KochsG.,
FeldmannH.,
HertkornC.,
HallerO.1996; Inhibition of bunyaviruses, phleboviruses and hantaviruses by human MxA protein. Journal of Virology 70:915–923
GresserI.,
ToveyM. G.,
BanduM. T.,
MauryC.,
Brouty-BoyeD.1976; Role of interferon in the pathogenesis of virus diseases, as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease and influenza viruses. Journal of Experimental Medicine 144:1316–1323
HarcourtB. H.,
SanchezA.,
OffermannM. K.1999; Ebola virus selectively inhibits responses to interferons, but not to interleukin-1β, in endothelial cells. Journal of Virology 73:3491–3496
HeftiH. P.,
FreseM.,
LandisH.,
Di PaoloC.,
AguzziA.,
HallerO.,
PavlovicJ.1999; Human MxA protein protects mice lacking a functional alpha/beta interferon system against La Crosse virus and other lethal viral infections. Journal of Virology 73:6984–6991
HugginsJ. W.,
ZhangZ.,
MonathT. I.1995; Inhibition of Ebola virus replication in vitro and in a SCID mouse model by S-adenosylhomocysteine hydrolase inhibitors. Antiviral Research Suppl. 1122
JaaxN.,
GeisbertT. W.,
VogelA.,
TopperM.,
JahrlingP.1996; Lethal experimental infection of rhesus monkeys with Ebola Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Archives of Pathology and Laboratory Medicine 120:140–155
PattynS.,
JacobW.,
van der GroenG.,
PiotP.,
CourteilleG.1977; Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire. Lancet i573–574
PetersC. J.,
RollinP.,
KsiazekT. G.,
MurphyF. A.1996; Filoviridae : Marburg and Ebola viruses In Fields Virology . pp 1161–1176 Edited by
FieldsB. N.,
KnipeD. M.,
HowleyP. M.
Philadelphia: Lippincott–Raven;
PfieferK.,
UshijimaH.,
LorenzB.,
MullerW. E.,
SchroderH. C.1993; Evidence for age-dependent impairment of antiviral 2′,5′-oligoadenylate synthetase/ribonuclease L-system in tissues of rat. Mechanisms of Ageing and Development 67:101–114
SullivanN. J.,
SanchezA.,
RollinP. E.,
YangZ.-Y.,
NabelG. J.2000; Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605–609
TrgovcichJ.,
AronsonJ. F.,
EldridgeJ. C.,
JohnstonE. E.1999; TNF-alpha, interferon and stress response induction as a function of age-related susceptibility to fatal Sindbis virus infection of mice. Virology 263:339–348
van den BroekM. F.,
MullerU.,
HuangS.,
AguetM.,
ZinkernagelR. M.1995a; Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. Journal of Virology 69:4792–4796
van den BroekM. F.,
MullerU.,
HuangS.,
ZinkernagelR. M.,
AguetM.1995b; Immune defense in mice lacking type I and/or type II interferon receptors. Immunological Reviews 148:5–18
VanderzandenL.,
BrayM.,
FullerD.,
RobertsT.,
CusterD.,
SpikK.,
JahrlingP.,
HugginsJ.,
SchmaljohnA.,
SchmaljohnC.1998; DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 246:134–144